Min Wu

TL;DR: This study suggests that a redox-mediated pathway contributes to the intrinsic resistance of PDAC to gemcitabine and provides a basis for developing strategies to preferentially kill PDAC cells through ROS-mediated mechanism.

TL;DR: Anakinra, an FDA-approved drug that inhibits IL-1 receptor (IL-1R), when given with or without gemcitabine, can reduce tumor growth by inhibiting IL1α-induced NF-κB activity; this result suggests that it is a useful therapeutic approach for PDAC.

TL;DR: It is suggested that NOX4, an enzyme known to catalyse the oxidation of NAD(P)H oxidase 4, is a potential therapeutic target for PDAC by providing a biochemical explanation for the cooperation between p16 inactivation and Kras activation in PDAC development.

TL;DR: The current data demonstrate that NBDP sensitizes human pancreatic cancer to gemcitabine by inhibiting the NF-κB pathway and is a potential adjuvant chemotherapeutic agent for treating pancreaticcancer.

TL;DR: A genetic profile of lncRNAs in pancreatic ductal adenocarcinoma remains an ongoing study and the role of long non‐coding RNA (lncRNA) in cancer progression is emphasized.